Inhibition of focal adhesion kinase with her-2 targeted antibody pertuzumab (Omnitarg®, 2C4) in breast cancer cells

dc.citation.epage300en_US
dc.citation.issueNumber2en_US
dc.citation.spage293en_US
dc.citation.volumeNumber12en_US
dc.contributor.authorCanbay, E.en_US
dc.contributor.authorGur-Dedeoglu, B.en_US
dc.contributor.authorBozkurt, B.en_US
dc.contributor.authorKarabeyoglu, M.en_US
dc.contributor.authorUnal, B.en_US
dc.contributor.authorYildirim, O.en_US
dc.contributor.authorCengiz, O.en_US
dc.contributor.authorYulug, I. G.en_US
dc.date.accessioned2016-02-08T10:06:21Z
dc.date.available2016-02-08T10:06:21Z
dc.date.issued2008en_US
dc.departmentDepartment of Molecular Biology and Geneticsen_US
dc.description.abstractPertuzumab (Omnitarg®, 2C4) is a recombinant humanized monoclonal antibody targeted to extracellular region of HER-2. Previous results proved the inhibitory effect of Pertuzumab on the survival of breast cancer cells via MAPK and Akt pathway. Focal adhesion kinase (FAK) regulates multiple cellular processes including growth, differentiation, adhesion, motility and apoptosis. Here, we aimed to investigate the effects of Pertuzumab on ligand activated total FAK expression and phosphorylation in the HER-2 overexpressing BT-474 breast cancer cell line. Heregulin was used for ligand activation. We have found that FAK expression and phosphorylation were inhibited in with Pertuzumab in breast cancer cells.en_US
dc.description.provenanceMade available in DSpace on 2016-02-08T10:06:21Z (GMT). No. of bitstreams: 1 bilkent-research-paper.pdf: 70227 bytes, checksum: 26e812c6f5156f83f0e77b261a471b5a (MD5) Previous issue date: 2008en
dc.identifier.issn1529-9120
dc.identifier.urihttp://hdl.handle.net/11693/22908
dc.language.isoEnglishen_US
dc.publisherGene Therapy Pressen_US
dc.source.titleGene Therapy and Molecular Biologyen_US
dc.subject2C4en_US
dc.subjectBreast canceren_US
dc.subjectFocal adhesion kinaseen_US
dc.subjectOmnitargen_US
dc.subjectPertuzumaben_US
dc.titleInhibition of focal adhesion kinase with her-2 targeted antibody pertuzumab (Omnitarg®, 2C4) in breast cancer cellsen_US
dc.typeArticleen_US

Files

Original bundle

Now showing 1 - 1 of 1
Loading...
Thumbnail Image
Name:
Inhibition of focal adhesion kinase with her-2 targeted antibody pertuzumab (Omnitarg®, 2C4) in breast cancer cells.pdf
Size:
464.97 KB
Format:
Adobe Portable Document Format
Description:
Full printable version